De-intensification for HPV positive oropharyngeal cancer: and yet it moves!
2019 in review

Pierluigi Bonomo1,*, Lorenzo Livi
Radiation Oncology, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy

ARTICLE INFO
Article history:
Received 8 February 2020
Revised 3 March 2020
Accepted 5 March 2020
Available online 7 March 2020

Keywords:
Head and neck cancer
Oropharynx
HPV
Radiotherapy
De-intensification

ABSTRACT
In the last decade, the recognition of the strongly positive prognostic impact of human papilloma virus (HPV) infection on the natural history of squamous cell carcinoma of the oropharynx has reshaped the historical monolithic view of a "one-size-fits-all approach" for head and neck cancer. Unlike their HPV negative counterparts, patients affected by HPV positive oropharyngeal cancer are usually in their prime with a low burden of comorbidities: most importantly, they are less likely to die for their disease, for second primary tumors or for intercurrent mortality. On these grounds, the scientific community was confronted with a pragmatic question: can the morbidity induced by standard concurrent chemo-radiotherapy be reduced without compromising efficacy? Worldwide, several prospective studies were launched, with the common aim to look for alternative treatment paradigms in the frame of de-intensification. This mini-review focuses on three new important trials published in 2019 and discusses their potential implications for clinical practice in the management of patients with HPV positive oropharyngeal cancer.

© 2020 Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Contents
1. Discussion .......................................................... 40
Declaration of Competing Interest ..................................................... 42
References ................................................................. 42

1. Discussion
Anticipated by presentations at international conferences and early online access in Fall 2018, the NRG Oncology RTOG 1016 [1] and De-ESCALaTE [2] trials were simultaneously published in the Lancet in January 2019. Their findings have been echoing at meetings all year long. After 12 months, the dust has settled. These two large phase 3 randomized studies were designed to explore the replacement of cisplatin with cetuximab in addition to radiotherapy (RT) as a de-intensified strategy for human papilloma virus (HPV) - positive oropharyngeal cancer (OPC). The assumption proved to be wrong in both trials.

In RTOG 1016, 849 patients were randomised to receive two cycles of cisplatin (100 mg/m² every 3 weeks) or cetuximab (400 mg/m² loading dose, then 250/m² weekly) on top of moderately accelerated IMRT, as per US standard (70 Gy in 35 fractions over 6 weeks). The primary endpoint was to demonstrate a non-inferior overall survival (OS) in the cetuximab arm, hypothesizing a 1-sided, upper boundary of hazard ratio (HR) inferior to 1.45. At a median follow-up of 4.5 years, 5-year OS was significantly better in patients who received cisplatin (84.6% vs 77.9%, p = 0.01; non-inferiority for cetuximab not shown with actual HR of 1.45, 95% upper CI 1.94). In De-ESCALaTE, 334 patients were randomly allocated to have 3 cycles of 3-weekly cisplatin or cetuximab (both at usual dosage) in combination with conventionally fractionated...
IMRT (70 Gy in 35 fractions in 7 weeks). The primary endpoint was to detect a reduction of more than 25% in the cumulative incidence of G3-G5 toxicities in the cetuximab arm. At a median follow-up of 25.9 months, no statistically significant difference could be demonstrated: the same mean number per patient of severe acute and late adverse events was reported (4.8; p = 0.98) in both arms, based on the TAME [3] method. The use of cetuximab was not associated with a benefit in terms of patient-reported quality of life either.

The quest for de-intensification in HPV positive OPC traces back to almost 10 years ago [4]. In the first pivotal publication of RTOG 0129 trial, Kian Ang and colleagues highlighted the strong, independent prognostic impact of immunohistochemical p16 positivity, as proxy for HPV infection. Compared to HPV-negative counterparts, a consistent 60% reduction in risks of death and disease progression was reported in a number of post-hoc analyses of phase 3 trials [5]. In view of the rising epidemiologic trend of HPV-related OPC [6] with a median age at diagnosis usually well below 65 years [7], the exquisite radiosensitivity observed in these patients [8] and the unquestionable burden of toxicity bound to concurrent cisplatin-based chemoradiotherapy [9], several strategies were envisaged with the aim to de-intensify treatment morbidity without compromising efficacy [10,11]. In this framework, substituting cetuximab for cisplatin in conjunction with RT was viewed as a rationale approach. In the pre-HPV era, the IMCL 9815 trial [12] showed that the addition of cetuximab to RT yielded a magnitude of benefit in survival much comparable to what obtained with chemotherapy, without an appreciable increase in toxicity. However, these results were ultimately biased by the everlasting absence of a direct comparison with concurrent cisplatin. In addition, the lack of predictive biomarkers for anti-EGFR blockade in head and neck squamous cell carcinoma (HNSSC) [13] and the suboptimal tolerability of cetuximab in clinical practice [14,15] limited its use to a large extent. Controversial data emerged on its specific efficacy for HPV positive patients, as well [16].

After 13 years from the publication of the IMCL 9815 trial, the negative results of NRG Oncology RTOG 1016 and De-ESCALaTE put an end to the supposed interchangeability of cetuximab and cisplatin as best radiosensitizing agent in HNSSC. Taking both trials together, bio-radiotherapy was significantly less effective than cheemo-radiotherapy. The overall rate of ≥3 toxicity was equivalent between the two combinations, with expected distinct profiles. In De-ESCALaTE, only the incidence of serious adverse events (SAEs) was lower (mean rate of events per patient: 0.6 vs 1, p < 0.001) mainly due to more hospitalizations in the cisplatin arm. The pending results of TROG 12.01 [17] will provide the complete picture, by comparing cetuximab – RT with weekly cisplatin (40 mg/m²) in terms of symptom severity assessed with MD Anderson Symptom Inventory Head and Neck Cancer (MDASI-HN) severity score. One-hundred eighty-nine patients were randomized in this trial until June 2018. In locally advanced HNSSC, the use of bio-radiotherapy remains confined as a possible option for patients unfit for cisplatin, albeit supported by limited prospective evidence [18] in this specific category. For the time being, concurrent three-weekly cisplatin based-chemoradiotherapy remains the standard non-surgical approach for all patients with HPV positive OPC suitable to this intensive regimen.

Some caution may be advised when extrapolating the described findings to current practice. RTOG 1016 was an “all-comers” trial restricted to the HPV positive population: overall, about 15% among those who received cisplatin ultimately succumbed from their disease, and 20% experienced disease progression. The accrual of the trial was accomplished over just 3 years, probably reflecting a large inclusion of low disease burden cases (71% low risk per RTOG 0129 classification). Only 12% and 4% of patients enrolled had T4 and N3 disease, respectively, but roughly 40% of the whole sample were heavy smokers (>10 pack/years). The relatively mixed composition of study population somewhat hampers the interpretation of the efficacy data in light of the 3-staged prognostic stratification of non-metastatic HPV positive OPC outlined in TNM 8th edition. Clearly, it should also be born in mind that although the number of pack-years was established as a significant determinant of OS in the Ang classification, the smoking history is a very weak surrogate of complex underlying etiology [19] and represents an ambiguous factor for patients’ selection. In addition, less than 15% of accrued patients were older than 65 in both RTOG 1016 and De-ESCALaTE. The epidemiologic trend of HPV positive OPC is rapidly evolving [20,21], with a projected increase of incidence in the elderly of 50% in the next decade. Very limited information obtained from the two trials is therefore applicable to their management.

In last 15 years, the recognition of a HPV epidemic in HNSCC was accompanied by a resurgence of interest in head and neck surgery for OPC through the introduction of transoral robotic surgery (TORS) [22]. The availability of optimized, less morbid surgical techniques for transoral resection and the intrinsically favorable biology of HPV driven OPC contributed to a renewed shift in the “swinging pendulum” [23] of disease management towards primary surgery. In the frame of de-intensification, 3 large randomized trials (ECOG 3311, ADEPT and PATHOS) were launched [24] to essentially test the efficacy and toxicity of a less intense sequence of treatment for resectable OPC, based on upfront minimally invasive surgery followed by a risk-adapted adjuvant strategy. The results of these studies will not be available soon. Meanwhile, the steady refinement of surgical and radiation techniques inspired the design of prospective head-to-head comparisons for the management of early stage OPC [25,26]. Thus far, equivalent disease control was assumed mainly from cross comparisons of retrospective data [27]. No insight was possible in regards to equipoise of treatment-related morbidity. In this view, the recent publication of the randomized phase 2 ORATOR trial [28] was welcomed as the the first of its kind. Sixty-eight patients with T1-T2, N0-N2 (less than 4 cm) OPC (88% HPV positive) were randomized to IMRT (with concurrent CT in case of node positive disease) or TORS plus neck dissection (with adjuvant treatment on the basis of pathological report). The study was designed to test the superiority of TORS in terms of MD Anderson Dysphagia Index (MDADI) one year after treatment, hypothesizing a clinically meaningful difference (10 points) in swallowing-related quality of life in respect to the RT arm. In contrast to this assumption, mean MDADI score was significantly better in patients receiving primary RT rather than being operated on with TORS (86.9 vs 80.1, p = 0.042) although this difference was below the prespecified threshold of clinical meaningfulness. A similar rate of grade 2 or worse adverse events was reported in both cohorts, with clearly distinct profiles. The supposed less morbidity associated with the use of minimally invasive surgery for early stage OPC was therefore not demonstrated. Whatever direction the pendulum is swinging, expertise [28] and quality of care [29] are of pivotal importance in ensuring the best chance of disease control.

Eagerly awaiting for what’s yet to come, very relevant insights on HPV positive OPC management were presented in 2019 (Table 1). Overall, it is not the proper time for de-intensification for any HPV positive patient yet, outside of clinical trials. Still, undisputed progress in knowledge was made possible by formally negative trials such as NRG Oncology RTOG 1016, De-ESCALaTE and ORATOR. Cisplatin-based concurrent chemoradiotherapy is still the one-size-fits-all approach for locally advanced HNSSC, far from being a desirable strategy. Nothing has truly changed in the field of de-intensification and the monothetic view of head and neck cancer management has still not been replaced, but...


| Table 1 | Main message | Primary outcome measure | Regimens | Clinical stage (N/IIA stage) | Study design (no. of patients) | Median follow-up (years) | Smoking history (pack-years) | Median smoking history (pack-years) | Overall survival (non-inferiority met if the HR for the HR was <1.45) | Non-inferiority of Cetuximab-RT vs Cisplatin-RT not shown (one-sided 95% CI upper boundary: 1.94) | Non-clinically significant higher mean number of events per patient (CTCAE v4.3 for a period of 24 months from the end of treatment) | Non-clinically significant higher mean number of events per patient was 29.2 (95% CI 28.3–31.9; p=0.48) | Same mean number of severe events per patient (N/IIA method) in both arms: 4.8 (95% CI 4.2–5.4; p=0.98) | All-grade toxicity: mean number of events per patient was 27.3 (95% CI 26.1–28.5; p=0.21) | Non-significant higher mean number of adverse events (C2/ESCALATE) in the Cetuximab 400 mg/m² then 250 mg/m² q1w versus 70 Gy/35 fx in 7 weeks RT: Radiotherapy; fx: fractions; CI: confidence intervals; HR: hazard ratio; OS: overall survival; CTCAE: Common Terminology Criteria for Adverse Events; MDADI: MD Anderson Dysphagia Inventory; CR: chemotherapy.

**Main characteristics of 3 analyzed trials.**

- **NRG Oncology RTOG 1016**: Randomized, non-inferiority phase 3 trial (n = 987) with Cisplatin 40 mg/m² then Cetuximab 400 mg/m² then Cisplatin 40 mg/m² then Cetuximab 400 mg/m² then Cetuximab 400 mg/m² then Cetuximab 400 mg/m² then Cetuximab 400 mg/m² then 250 mg/m² q1w RT: Radiotherapy; fx: fractions; CI: confidence intervals; HR: hazard ratio; OS: overall survival; CTCAE: Common Terminology Criteria for Adverse Events; MDADI: MD Anderson Dysphagia Inventory; CR: chemotherapy.

- **De-ESCALaTE**: Randomized phase 3 trial (n = 334) with RT: Radiotherapy; fx: fractions; CI: confidence intervals; HR: hazard ratio; OS: overall survival; CTCAE: Common Terminology Criteria for Adverse Events; MDADI: MD Anderson Dysphagia Inventory; CR: chemotherapy.

- **ORATOR**: Randomized controlled phase 3 trial (n = 334) with RT: Radiotherapy; fx: fractions; CI: confidence intervals; HR: hazard ratio; OS: overall survival; CTCAE: Common Terminology Criteria for Adverse Events; MDADI: MD Anderson Dysphagia Inventory; CR: chemotherapy.

**References**

[1] Gillison ML, Trotti AM, Harris H, Eisbruch A, Harari PM, Adelstein DJ, et al. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): A randomised, multicentre, non-inferiority trial. Lancet 2019;393(10166):40–50.

[2] Mehnas H, Robinson M, Hartley A, Keng A, Foran B, Liew-Fulton T, et al. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): An open-label randomised controlled phase 3 trial. Lancet 2019;393(10166):51–60.

[3] Trotti A, Pajak TF, Gwede CK, Paulus R, Cooper J, Forastiere A, et al. TAME: Development of a new method for summarising adverse events of cancer treatment by the Radiation Therapy Oncology Group. Lancet Oncol 2007;8(7):613–24.

[4] Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010;363(1):24–35.

[5] Taberna M, Mena M, Pavon MA, Alemany L, Gillison ML, Mesia R. Human papillomavirus-positive head and neck squamous cell carcinoma tumor location: A virus-related cancer epidemic. Lancet Oncol 2010;11:781–9.

[6] Gillison ML, Chaturvedi AK, Anderson WF, Fakhry C. Evolution of the oropharynx cancer epidemic in the United States: Moderation of increasing incidence in younger individuals and shift in the burden to older individuals. J Clin Oncol 2019;37(18):1538–46.

De-ESCALaTE: A randomised phase II trial. J Clin Oncol 2013;31(20):2477–85.

Evolution of the oropharynx cancer epidemic in the United States: Moderation of increasing incidence in younger individuals and shift in the burden to older individuals. J Clin Oncol 2019;37(18):1538–46.
[22] Holsinger FC, Ferris RL. Transoral endoscopic head and neck surgery and its role within the multidisciplinary treatment paradigm of oropharynx cancer: Robotics, lasers, and clinical trials. J Clin Oncol 2015;33(29):3285–92.

[23] Holsinger FC, Weber RS. Swing of the surgical pendulum: A return to surgery for treatment of head and neck cancer in the 21st century? Int J Radiat Oncol Biol Phys 2007;69:S129–31.

[24] Howard J, Dwivedi RC, Masterson L, Kothari P, Quon H, Holsinger FC. De-intensified adjuvant (chemo)radiotherapy versus standard adjuvant chemoradiotherapy post transoral minimally invasive surgery for resectable HPV-positive oropharyngeal carcinoma Cochrane Database Syst Rev 12 2018 CD012939

[25] Stelmes JJ, Gregoire V, Poorten VV, Golusiñski W, Szewczyk M, Jones T, et al. Organ preservation and late functional outcome in oropharyngeal carcinoma: Rationale of EORTC 1420, the “Best of” trial. Front Oncol 2019;9:999.

[26] Nichols AC, Theurer J, Prisman E, Read N, Berthelet E, Tran E, et al. Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): An open-label, phase 2, randomised trial. Lancet Oncol 2019;20(10):1349–59.

[27] Morisod B, Simon C. Meta-analysis on survival of patients treated with transoral surgery versus radiotherapy for early-stage squamous cell carcinoma of the oropharynx. Head Neck 2016;38(Suppl 1):E2143–50.

[28] Corry J, Peters LJ, Rischin D. Impact of center size and experience on outcomes in head and neck cancer. J Clin Oncol 2015;33(2):138–40.

[29] Strober WA, Sridharan S, Duvvuri U, Cramer JD. Variation in the quality of head and neck cancer care in the United States. JAMA Otolaryngol Head Neck Surg 2019;145(2):188–91.

[30] Hawking S. On the shoulders of giants: The great works of physics and astronomy. Running Press 2003:396–7.